Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Efficacy and tolerability… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Efficacy and tolerability of reboxetine compared with citalopram: a double-blind study in patients with major depressive disorder.

Artikel i vetenskaplig tidskrift
Författare Sven Langworth
Owe Bodlund
Hans Ågren
Publicerad i Journal of clinical psychopharmacology
Volym 26
Nummer/häfte 2
Sidor 121-7
ISSN 0271-0749
Publiceringsår 2006
Publicerad vid Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi
Sidor 121-7
Språk en
Länkar dx.doi.org/10.1097/01.jcp.000020413...
Ämnesord Adolescent, Adult, Aged, Antidepressive Agents, Second-Generation, administration & dosage, adverse effects, therapeutic use, Antidepressive Agents, Tricyclic, administration & dosage, adverse effects, therapeutic use, Citalopram, administration & dosage, adverse effects, therapeutic use, Depressive Disorder, Major, drug therapy, Double-Blind Method, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Morpholines, administration & dosage, adverse effects, Patient Dropouts, Psychiatric Status Rating Scales, Sexual Dysfunction, Physiological, etiology, Xerostomia, etiology
Ämneskategorier Psykiatri

Sammanfattning

The objective of this study was to compare efficacy and tolerability of the selective noradrenaline reuptake inhibitor reboxetine with the selective serotonin reuptake inhibitor citalopram, in the treatment of major depressive disorder (MDD). In total, 357 outpatients with MDD were randomized to treatment with reboxetine 8-10 mg or citalopram 20-40 mg per day during 24 weeks. Primary end-point was change from baseline in the Hamilton Depression Rating Scale (HAM-D, 21 items). Sexual function/dysfunction was measured by the Sexual Function scale (SF). Observed case analysis showed that both treatments yielded a gradual reduction of HAM-D scores: reboxetine with -21.4 and citalopram with -22.1 points (NS). LOCF analysis showed a greater reduction of the HAM-D scores with citalopram compared with reboxetine (-19.6 vs. -17.8; P = 0.034). The response rate was 90.3% for reboxetine and 92.7% for citalopram (NS). The most common side effect in the reboxetine group was dry mouth, and in the citalopram group sexual dysfunction. At week 24, anorgasmia was reported by 5.9% of the sexually active women in the reboxetine group vs 39% in the citalopram group. The dropout number was 91 in the reboxetine group, and 54 in the citalopram group. To summarize, both treatments gave a satisfactory antidepressant effect. The side effect profile differed between the groups, with a notably high prevalence of sexual dysfunctions in the citalopram group. The high number of dropouts in the reboxetine group, is considered as a result of the non-titration starting dose of 8 mg reboxetine per day, which gave a high incidence of early side-effects.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?